EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Treatment (EGFR-TKI Inhibitors...

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Size

Market Size in USD Bn

CAGR7.9%

Study Period2025-2032
Base Year of Estimation2024
CAGR7.9%
Market ConcentrationHigh
Major PlayersAstraZeneca, Janssen Pharmaceuticals, Pfizer, Roche, Novartis and Among Others
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
setting-icon
Want to purchase customized report?
please let us know !

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Analysis

The EGFR non-small cell lung cancer (EGFR + NSCLC) market is estimated to be valued at USD 4.65 Bn in 2025 and is expected to reach USD 7.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The increasing prevalence of lung cancer across the world and rising focus on targeted therapies to treat NSCLC are fueling the growth of this market.

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Report Snapshots

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Size